author-photo

Christina Hong

Memorial Sloan Kettering Cancer Center

5

Papers

122

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

2013 Cancer
Show All
- Source
- Cite
- Save
Citations (20)
Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer

2009 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (82)
Phase I study of docetaxel (Tax) and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC)

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)